Skip to content

Wegovy vs Mounjaro: approved uses, doses, cost and coverage

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Wegovy vs Mounjaro starts with the label. Mounjaro (tirzepatide) is approved for type 2 diabetes. Wegovy (semaglutide) is approved for weight reduction and cardiovascular risk reduction, as a weekly pen or a daily pill. Manufacturer self-pay prices are $499 a month for Mounjaro through LillyDirect and $349 for the Wegovy 2.4 mg pen through NovoCare Pharmacy.

Source: LillyDirect self-pay

Key takeaways

  • Both of Mounjaro's approved uses require type 2 diabetes. Its label has no weight-management use.
  • Wegovy is approved for long-term weight reduction, and for cardiovascular risk in adults with established disease and obesity or overweight.
  • Want a pill? Only Wegovy has one. Mounjaro is an injection in every form.
  • Paying cash? Mounjaro is $499 a month through LillyDirect. The Wegovy 2.4 mg pen is $349 through NovoCare.
  • No trial on either label compares Mounjaro with Wegovy, and no label converts one dose into the other.

Mounjaro vs Wegovy, side by side

From each FDA label and our verified price records
MounjaroWegovy
Active ingredienttirzepatidesemaglutide
MakerEli Lilly and CompanyNovo Nordisk
FDA-approved uses
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events
  • Reduce the risk of major adverse cardiovascular events in adults with established CV disease and either obesity or overweight (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity (injection)
  • Reduce excess body weight and maintain weight reduction long term in adults with overweight and at least one weight-related comorbid condition (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults with obesity (tablets)
  • Treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults, under accelerated approval (injection)
How it is takenweekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)weekly (single-dose pen); daily (tablet)
Strengths2.5 to 15 mg0.25 to 25 mg
Label starting dose
  • 2.5 mg weekly
  • 0.25 mg weekly
  • 1.5 mg daily
Cheapest verified self-pay$499 per fill at 15 mg
LillyDirect self-pay
$299 per fill at 25 mg
NovoCare self-pay
With covering commercial insurance$25 with the manufacturer card$25 with the manufacturer card
Medicare GLP-1 BridgeNoYes: Single-dose pen (7.2 mg pen is branded WEGOVY HD); Tablet (once daily)
LabelRevised: 8/2026 (DailyMed version 40)Revised: 6/2026 (DailyMed version 19)
Mounjaro: most common reactions on the label · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
Reaction15 mgPlacebo
Nausea18%4%
Diarrhea17%9%
Decreased Appetite11%1%
Vomiting9%2%
Constipation7%1%
Dyspepsia5%3%
Wegovy: most common reactions on the label · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionWegovy injection 2.4 mg once weeklyPlacebo
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%
Abdominal Pain20%10%
Headache14%10%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Mounjaro and Wegovy are both weekly injections from the GLP-1 family, but their FDA labels approve them for different conditions. That one difference decides most of what follows: which of the two a prescriber can write for you, whether insurance pays, and which cash price applies. This page sets them side by side using the FDA labels (Revised: 8/2026 (DailyMed version 40) for Mounjaro, Revised: 6/2026 (DailyMed version 19) for Wegovy) and our price records.

Mounjaro or Wegovy: which suits whom?

  • You have type 2 diabetes. Mounjaro is approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, and to reduce major cardiovascular events (serious heart and blood vessel events) in adults with type 2 diabetes who are at high risk. Its label has no weight-management use.
  • You’re being treated for weight, or for heart risk linked to weight. Wegovy is approved for long-term weight reduction, and to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The injection is also approved for the liver condition MASH.
  • You want a pill. Only Wegovy has one. Mounjaro is an injection in every form.
  • You’re paying cash. Mounjaro is $499 a month at every strength through LillyDirect. Wegovy runs from $149 a month for the lowest tablet strength to $399 for the 7.2 mg pen through NovoCare Pharmacy.
  • You’re on Medicare. Mounjaro goes through your Part D plan as a diabetes medicine. Wegovy for weight management goes through the Medicare GLP-1 Bridge at a $50 monthly copay, and the Bridge is closed to people with type 2 diabetes.

Neither label says one medicine works better than the other, and no trial on either label compares Mounjaro with Wegovy. If you have type 2 diabetes and are also thinking about your weight, ask your prescriber which label fits what you’re being treated for, and ask your plan what it pays for under each.

What is each one approved for?

Mounjaro contains tirzepatide and is made by Eli Lilly. Wegovy contains semaglutide and is made by Novo Nordisk. They’re different molecules with separate labels.

Both of Mounjaro’s approved uses require type 2 diabetes. The label also says it isn’t recommended for people with severe gastroparesis (very slow stomach emptying). The tirzepatide brand whose label covers weight reduction is Zepbound, so if weight management is the goal, Wegovy vs Zepbound is the closer comparison.

Wegovy’s uses don’t all apply to both of its forms. Weight reduction and cardiovascular risk reduction are on the label for the injection and the tablets, though only the injection is approved from age 12. MASH is approved for the injection only, under accelerated approval.

Is there a head-to-head trial?

Not between these two brands. The Mounjaro label does report one trial against semaglutide, the molecule in Wegovy, but at a diabetes dose and for a diabetes outcome. In SURPASS-2, a 40-week trial in adults with type 2 diabetes taking metformin, HbA1c (a measure of average blood sugar over recent months) changed by -2.0, -2.2 and -2.3 percentage points on Mounjaro 5 mg, 10 mg and 15 mg, versus -1.9 with semaglutide 1 mg.

The semaglutide arm was 1 mg once weekly, for blood sugar control. Wegovy’s usual maintenance dosage (the dose you stay on) is 2.4 mg. So SURPASS-2 isn’t a Mounjaro versus Wegovy result, and it says nothing about weight management.

How do the doses and forms differ?

Mounjaro comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The label starts at 2.5 mg once weekly and raises the dose in 2.5 mg steps, each after at least 4 weeks, only if more blood sugar control is needed. The maximum is 15 mg once weekly in adults and 10 mg in children. The label lists a single-dose pen, a single-dose vial, a KwikPen and a multi-dose vial. Every Mounjaro price we hold is for the single-dose pen.

The Wegovy pen comes in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg. It starts at 0.25 mg once weekly and steps up every 4 weeks, reaching the usual maintenance dosage of 2.4 mg from week 17. The 7.2 mg pen (Wegovy HD) is an optional step for adults taking Wegovy for weight reduction who have tolerated 2.4 mg for at least 4 weeks.

The Wegovy tablet comes in 1.5 mg, 4 mg, 9 mg, 25 mg and is taken once daily. It has rules the injections don’t: in the morning, on an empty stomach, with up to 4 ounces of water, then a wait of at least 30 minutes before food, other drinks or other oral medicines.

The missed-dose rules differ too. The missed dose tool applies each label’s rule to your dates, and the titration schedule tool lays out either dose path on a calendar.

What does each one cost?

The prices are:

Mounjaro (single-dose pen)

  • LillyDirect self-pay: $499 a month, the same at every strength.
  • Savings card with commercial insurance that covers it: as little as $25 a fill.
  • List price (the full price before any discount): $1,112.16 per fill of four pens.

Wegovy

  • NovoCare self-pay, pen: $349 a month at 1 mg, 1.7 mg and 2.4 mg, and $399 for 7.2 mg. If you’re new to the offer, you pay $199 a month for up to two fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349.
  • NovoCare self-pay, tablets: $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg.
  • Savings offer with commercial insurance that covers it: as little as $25 a month.
  • List price: $1,349.02 per package.

Both pens are filled every 28 days, which makes 13 fills a year. A full year at one dose comes to $6,487 for Mounjaro through LillyDirect and $4,537 for the Wegovy 2.4 mg pen through NovoCare.

The savings cards are for people with commercial insurance, and both exclude anyone on Medicare, Medicaid or another government program. The Mounjaro cost guide and the Wegovy cost guide go through each route, and the cost calculator prices your own dose path.

Does insurance or Medicare cover them?

Insurers treat these as different drugs for different conditions. A commercial plan may list Mounjaro for type 2 diabetes, often with prior authorization (the plan’s approval before it pays) or proof of the diagnosis, and at the same time exclude weight-management medicines such as Wegovy altogether. Call the number on your insurance card and ask about each brand for your diagnosis.

For Medicare, the split is sharper:

  • Mounjaro. CMS states that type 2 diabetes is an indication eligible for Part D coverage, so Mounjaro is a matter for your Part D plan’s formulary (its list of covered drugs). It isn’t part of the Medicare GLP-1 Bridge.
  • Wegovy. CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. There are two routes. Part D can cover Wegovy when it’s prescribed to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. And the Bridge covers the Wegovy pen and tablets for weight management at a $50 copay per one-month supply through December 31, 2027.

People with type 2 diabetes aren’t eligible for the Bridge, so the two routes rarely overlap for one person. See does Medicare cover Wegovy and the Bridge guide.

How do the side effects compare?

Each label reports its own trials, in different patients and at different doses, so the figures below describe each medicine separately. They aren’t a ranking.

Mounjaro. In the label’s pool of two placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 12, 15 and 18 percent of people on 5 mg, 10 mg and 15 mg, versus 4 percent on placebo. More people stopped treatment because of gastrointestinal (stomach and bowel) reactions on Mounjaro (3.0%, 5.4% and 6.6% across the three doses) than on placebo (0.4%).

Wegovy. In the label’s adult weight-reduction trials of the 2.4 mg injection, nausea was reported by 44 percent of patients, versus 16 percent on placebo. In those trials, 6.8% of patients on Wegovy and 3.2% on placebo stopped treatment permanently because of adverse reactions. For the 25 mg tablets, the label says the types and frequency of common reactions were similar to those of the injection.

Both carry a boxed warning about thyroid C-cell tumors. Neither should be used by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it).

Can you switch between Mounjaro and Wegovy?

The labels give little to go on. The Mounjaro label has no instructions for switching from another GLP-1 medicine. It gives only its starting dose. The Wegovy label’s switching instructions cover moves between its own pen and tablet, such as from the 2.4 mg injection to the 25 mg tablet. And the Wegovy label says using it together with any other GLP-1 receptor agonist isn’t recommended.

So no label converts a Mounjaro dose to a Wegovy dose or the reverse, and we don’t offer a conversion. Your prescriber decides where you start, and when. Our switching guides and the switching planner show what each label says. More pairings are on the comparison hub.

Frequently asked questions

What is the difference between Mounjaro and Wegovy?

They're different medicines with different approved uses. Mounjaro contains tirzepatide and is approved for type 2 diabetes in adults and children 10 and older. Wegovy contains semaglutide and is approved for long-term weight reduction and for lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. Wegovy also comes as a daily tablet, while Mounjaro is injection only.

Is Mounjaro or Wegovy cheaper without insurance?

Mounjaro costs $499 a month at every strength through LillyDirect. The Wegovy pen costs $349 a month at 1 mg, 1.7 mg and 2.4 mg through NovoCare Pharmacy, and Wegovy tablets start at $149 a month. A lower cash price doesn't change which medicine your diagnosis supports.

Is Mounjaro approved for weight loss?

No. Mounjaro's label lists two uses, both in type 2 diabetes: blood sugar control, and reducing major cardiovascular events in adults at high risk. The tirzepatide brand approved for long-term weight reduction is Zepbound, which has its own label, prices and savings programs. Wegovy's label does include weight reduction.

Can I take Mounjaro and Wegovy together?

The Wegovy label says using it together with other semaglutide products or with any other GLP-1 receptor agonist isn't recommended. If your prescriber moves you from one medicine to the other, they write a new prescription for the new one. Neither label gives a dose conversion between the two, and we don't publish one.

Does Medicare cover Mounjaro or Wegovy?

Type 2 diabetes is a use Part D can cover, so Mounjaro runs through your Part D plan and its formulary. Wegovy for weight management is available to eligible Part D patients through the Medicare GLP-1 Bridge at a $50 monthly copay, and Part D can cover Wegovy when it's prescribed to reduce cardiovascular risk. People with type 2 diabetes aren't eligible for the Bridge.

Sources (19)

  1. 1.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.3, Table 5
    “Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin. HbA1c (%) - Change at Week 40: Semaglutide 1 mg: -1.9; MOUNJARO 5 mg: -2.0; MOUNJARO 10 mg: -2.2; MOUNJARO 15 mg: -2.3”
  2. 2.
    FDA label (DailyMed): Mounjaro prescribing information, section 5.6
    “MOUNJARO is not recommended in patients with severe gastroparesis.”
  3. 3.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  4. 4.
    FDA label (DailyMed): Wegovy prescribing information, section 4
    “a personal or family history of MTC or in patients with MEN 2”
  5. 5.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  6. 6.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
  7. 7.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
  8. 8.
    FDA label (DailyMed): Wegovy prescribing information, section 2.5
    “One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
  9. 9.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  10. 10.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
  11. 11.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.